- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.07. | PAINREFORM LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 26.06. | PAINREFORM LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 31.05. | PAINREFORM LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 31.05. | PainReform receives Nasdaq minimum bid price notification | 1 | Seeking Alpha | ||
| 31.05. | PainReform Ltd: PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification | 382 | GlobeNewswire (Europe) | TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of... ► Artikel lesen | |
| 16.05. | PainReform reports Q1 results | 1 | Seeking Alpha | ||
| 15.05. | PainReform Ltd: PainReform Provides Business Update for the First Quarter of 2024 | 107 | GlobeNewswire (Europe) | Reaches 50% enrollment in the second part of its Phase 3 clinical trial of PRF-110 in bunionectomy Remains on track to announce top-line data in Q3 2024 TEL AVIV, Israel, May 15, 2024 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 10.05. | PainReform Ltd expected to post a loss of $2.40 a share - Earnings Preview | 2 | Reuters | ||
| 08.05. | PainReform Ltd: PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com | 1 | GlobeNewswire (USA) | ||
| 18.04. | PainReform Ltd: PainReform Announces Closing of $4 Million Public Offering | 1 | GlobeNewswire (USA) | ||
| 16.04. | PainReform prices its $4M offering at $0.80 apiece; shares fall | 1 | Seeking Alpha | ||
| 16.04. | PAINREFORM LTD. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 15.04. | PAINREFORM LTD. - F-1/A, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| 09.04. | PAINREFORM LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 09.04. | PainReform Ltd: PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions | 88 | GlobeNewswire (Europe) | TEL AVIV, Israel, April 09, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation... ► Artikel lesen | |
| 09.04. | EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions | 1 | Benzinga.com | ||
| 02.04. | PAINREFORM LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 02.04. | PainReform Ltd: PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy | 104 | GlobeNewswire (Europe) | TEL AVIV, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation... ► Artikel lesen | |
| 02.04. | EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug | 1 | Benzinga.com | ||
| 01.03. | PainReform files to sell shares | 1 | Seeking Alpha |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ASTRIA THERAPEUTICS | 11,300 | +2,73 % | Astria Therapeutics, Inc.: Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress | Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two... ► Artikel lesen | |
| ROCKET LAB USA | 5,040 | +1,41 % | Mynaric AG: Mynaric Selected by Rocket Lab for Space Development Agency's Tranche 2 Transport Layer - Beta Program | Laser Communications Manufacturer Expands Customer RosterLOS ANGELES, CA / ACCESSWIRE / May 7, 2024 / Mynaric (NASDAQ:MYNA)(FRA:M0YN), a leading provider of industrialized, cost-effective and scalable... ► Artikel lesen | |
| BOIRON | 31,800 | 0,00 % | BOIRON: EVOLUTION OF GOVERNANCE | July 3rd, 2024
The Board of Directors of Laboratoires BOIRON, meeting today under the chairmanship of Thierry BOIRON, has enacted an evolution of the Group's governance.
In this context, Thierry... ► Artikel lesen | |
| HARROW | 24,440 | +0,87 % | Harrow, Inc.: Harrow to Attend 2024 ASRS Annual Meeting | Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual... ► Artikel lesen | |
| MEDICINOVA | 1,200 | -1,64 % | MediciNova, Inc.: MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 | LA JOLLA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
| ESSA PHARMA | 5,300 | -2,21 % | ESSA Pharma Inc: ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024 | Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC naïve to second generation antiandrogens... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,825 | +10,87 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports Positive Topline Data for Anaphylm (epinephrine) Sublingual Film from Self-Administration Study | Meets primary study endpoints with pharmacokinetics (PK) comparable whether Anaphylm is administered by subjects or by healthcare providers (HCPs)Final supportive study, the Oral Allergy Syndrome... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 1,240 | -1,59 % | Reviva Pharmaceuticals: Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension | - Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary... ► Artikel lesen | |
| CUMBERLAND PHARMACEUTICALS | 1,460 | 0,00 % | Cumberland Pharmaceuticals Inc.: Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update | NASHVILLE, TENN., May 7, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands... ► Artikel lesen | |
| CYANOTECH | 0,260 | 0,00 % | Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2024 | KAILUA KONA, Hawaii--(BUSINESS WIRE)--Cyanotech Corporation (OTCQB Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial... ► Artikel lesen | |
| SHINECO | 0,680 | 0,00 % | Shineco, Inc.: Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement | BEIJING, June 27, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a producer of innovative diagnostic medical products and related medical devices, announced today... ► Artikel lesen | |
| LYRA THERAPEUTICS | 0,306 | -0,97 % | Lyra Therapeutics, Inc. - 8-K, Current Report | ||
| OMNIAB | 4,835 | +0,73 % | OmniAb Reports First Quarter 2024 Financial Results and Business Highlights | EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates.
"The... ► Artikel lesen | |
| BAYER | 27,465 | -0,24 % | Bayer-Aktie an DAX-Spitze: Charttechnisch spannend | Mit einem Plus von gut drei Prozent rangiert das Papier von Bayer zu Wochenbeginn an der Spitze im DAX. Neuigkeiten von Unternehmens- oder Analystenseite, die die recht deutlichen Kursaufschläge begründen... ► Artikel lesen | |
| MERCK KGAA | 159,50 | +2,70 % | Merck Aktie: Kursrückgang trotz positiver Prognosen | Die Merck-Aktie verzeichnete am Freitag einen leichten Rückgang im XETRA-Handel. Trotz eines anfänglichen Kurses von 150,90 EUR sank der Wert im Tagesverlauf um 0,4 Prozent auf 149,05 EUR. Das Handelsvolumen... ► Artikel lesen |
PAINREFORM LTD gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 0,406 Euro und damit +6,28 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PAINREFORM LTD finden Sie auf Wallstreet Online.
